Charles Schwab Investment Management Inc. Increases Stake in Perspective Therapeutics, Inc. (NYSE:CATX)

Charles Schwab Investment Management Inc. raised its stake in Perspective Therapeutics, Inc. (NYSE:CATX) by 221.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 433,522 shares of the company’s stock after acquiring an additional 298,778 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Perspective Therapeutics were worth $5,788,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of CATX. nVerses Capital LLC acquired a new stake in Perspective Therapeutics during the third quarter valued at $57,000. US Bancorp DE increased its stake in shares of Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares in the last quarter. Intech Investment Management LLC acquired a new position in Perspective Therapeutics in the 3rd quarter worth about $137,000. Los Angeles Capital Management LLC purchased a new position in Perspective Therapeutics during the third quarter worth approximately $153,000. Finally, Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics in the second quarter valued at approximately $117,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

NYSE:CATX opened at $3.47 on Friday. Perspective Therapeutics, Inc. has a 52 week low of $2.28 and a 52 week high of $19.05. The stock’s fifty day moving average is $8.99 and its two-hundred day moving average is $11.59.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Equities research analysts predict that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Analysts Set New Price Targets

CATX has been the topic of a number of research analyst reports. Truist Financial started coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. Royal Bank of Canada dropped their target price on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research report on Monday, November 25th. UBS Group initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Finally, Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.14.

Insider Buying and Selling

In other news, CEO Johan M. Spoor acquired 8,000 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were bought at an average price of $3.77 per share, with a total value of $30,160.00. Following the completion of the acquisition, the chief executive officer now owns 36,257 shares in the company, valued at $136,688.89. This trade represents a 28.31 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Heidi Henson purchased 25,975 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were purchased at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the transaction, the director now owns 25,975 shares of the company’s stock, valued at $100,003.75. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 67,570 shares of company stock worth $256,789. Corporate insiders own 3.52% of the company’s stock.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.